Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

BTK Inhibitor-Containing Bridging Therapy and CAR-T Outcomes in R/R LBCL

Association of Disease Control After BTK Inhibitor-Containing Bridging Therapy and Systemic Inflammatory Phenotypes With CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

This observational study will examine outcomes of CAR-T cell therapy in adults with large B-cell lymphoma that has returned or has not responded to prior treatment. Participants will already have received bridging therapy that includes a BTK inhibitor before CAR-T cell infusion.

Researchers will compare outcomes between participants whose lymphoma responded to bridging therapy before CAR-T cell infusion and those whose lymphoma did not respond. The study will use medical records, imaging results, laboratory tests, treatment information, and follow-up data collected during usual care. It will not assign treatment, change medical care, or require extra tests or blood samples.

The study will assess lymphoma response after CAR-T cell therapy, safety, survival, and changes in routine blood markers of inflammation after CAR-T cell therapy.

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Antatt)

66

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

The study population comprises adults with relapsed or refractory large B-cell lymphoma (LBCL) who receive routine CAR-T cell therapy at a single center in China. Eligible patients receive BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy and have evaluable disease status after bridging therapy and before CAR-T cell infusion. Patients treated before ethics approval will be identified retrospectively from the center's CAR-T treatment records and routine medical records; eligible patients treated after ethics approval will be enrolled prospectively using the same criteria.

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 year.
  2. Relapsed or refractory large B-cell lymphoma (LBCL) after one or more prior lines of systemic therapy, including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS); diffuse large B-cell lymphoma transformed from follicular lymphoma (tFL); grade 3B follicular lymphoma (FL3B); primary mediastinal large B-cell lymphoma (PMBCL); and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit/triple-hit lymphoma, DHL/THL).
  3. Completion of CAR-T cell infusion at this center.
  4. Receipt of BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy.
  5. Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.
  6. Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.

Exclusion Criteria:

  1. Inability to verify the specific BTK inhibitor(s) used, treatment start and stop dates, or information on combination therapy, thereby precluding confirmation of exposure to BTK inhibitorcontaining bridging therapy.
  2. Absence of disease assessment data between bridging therapy and CAR-T cell infusion, with post-bridging disease status not determinable from imaging reports or medical records.
  3. Major discrepancies in key baseline or treatment data that persist after review of medical records, imaging, and treatment documentation, precluding determination of bridging exposure or group assignment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: OTHER

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Bridging Response (CR/PR)

Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort achieved complete response (CR) or partial response (PR). Treatments were determined as part of usual clinical care and were not assigned by the study.

Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study.

CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study.

No Bridging Response (SD/PD)

Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort had stable disease (SD) or progressive disease (PD). Treatments were determined as part of usual clinical care and were not assigned by the study.

Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study.

CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Best objective response rate after CAR-T cell infusion
Tidsramme: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.

The proportion of participants who achieve complete response (CR) or partial response (PR) at any time after CAR-T infusion and before first progression, death, initiation of new anti-lymphoma therapy, or last evaluable disease assessment. Participants without CR/PR before these events are classified as nonresponders; progression or death after CR/PR does not change responder status.

At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Duration of response
Tidsramme: From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.

Among participants who achieve CR or PR, duration of response is measured from the date of first documented CR or PR to disease progression or death from any cause, whichever occurs first. Participants without progression or death will be censored at the last evaluable disease assessment or before initiation of subsequent anti-lymphoma therapy.

From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.
Complete response rate at 1 month after CAR-T cell infusion
Tidsramme: Approximately 1 month after CAR-T cell infusion.
Approximately 1 month after CAR-T cell infusion.
Best complete response rate after CAR-T cell infusion
Tidsramme: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
Number of participants with CAR-T treatment-emergent adverse events
Tidsramme: From CAR-T cell infusion to last follow-up.

The number and percentage of participants with any adverse event occurring after CAR-T cell infusion will be reported. Safety events include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, prolonged cytopenia, death, and other clinically documented adverse events considered related to CAR-T cell therapy. CRS and ICANS will be graded according to ASTCT consensus criteria; other events will be collected from routine clinical, laboratory, and medical-record data.

From CAR-T cell infusion to last follow-up.
Objective response rate at 1 month after CAR-T cell infusion
Tidsramme: Approximately 1 month after CAR-T cell infusion.
Approximately 1 month after CAR-T cell infusion.
Objective response rate at 3 month after CAR-T cell infusion
Tidsramme: Approximately 3 months after CAR-T cell infusion.
Approximately 3 months after CAR-T cell infusion.
Complete response rate at 3 months after CAR-T cell infusion
Tidsramme: 3 months after CAR-T cell infusion
3 months after CAR-T cell infusion
Progression-free survival
Tidsramme: From CAR-T infusion to first progression, death, or last follow-up.
From CAR-T infusion to first progression, death, or last follow-up.
Overall survival
Tidsramme: From CAR-T infusion to death from any cause or last follow-up.
From CAR-T infusion to death from any cause or last follow-up.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

2. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere